Distinguished Scientific Fellow
Van Andel Research Institute
Grand Rapids, Michigan
Seeking to develop novel strategies to reduce drug resistance and metastasis in aggressive breast cancers.
Laboratory studies are conducted to test a new drug target for combination therapy in triple negative breast cancers.
This research may identify predictive biomarkers of response to targeted therapies and novel new combination approaches to counter drug resistance and prevent metastasis.
For a tumor to spread (a process called metastasis), tumor cells must be able to break through tissue barriers, enter the circulation, and become established in a new site. To achieve these steps, a tumor cell must acquire unique physical and molecular properties.
The research team of Drs. Vande Woude, Graveel and Tsarfaty have combined several unique laboratory models to evaluate how the Met oncogene influences breast cancer metastasis, metabolism, and drug resistance in HER2+ and triple negative breast cancers (TNBC). Their recent studies have identified potential combination approaches that could reduce drug resistance and prevent metastasis in these diseases.
The research team continues to study the role of Met in progression of HER2+ and triple negative breast cancer using a combination of novel imaging techniques and mathematical models and plan to test combination therapies against TNBC progression and metastasis in patient-derived TNBC models.
This research will enable development of novel molecular and imaging signatures, identify predictive biomarkers in patients who are responsive to Met-targeted therapies, and lead to the development of novel combination therapies.
Dr. George F. Vande Woude received his M.S. (1962) and PhD (1964) from Rutgers University. From 1964-1972, he served first as a postdoctoral research associate, then as a research virologist for the US Department of Agriculture at Plum Island Animal Disease Center. In 1972, he joined the National Cancer Institute and from 1983-1998 was the Director of the Advanced Bioscience Laboratories-Basic Research Program. In 1993, he was elected to the National Academy of Sciences and served as Chair of the Section for Medical Genetics, Hematology & Oncology (2004-2007). In 1999, he became the first Director of Van Andel Research Institute (VARI), a position he held until February 2009. He is currently a Distinguished Scientific Fellow at VARI.
Since the 1970s Dr. Vande Woude’s laboratory research has focused on understanding the molecular basis of cancer. Dr. Vande Woude’s laboratory was first to determine the structure and enhancer function of proviral long terminal repeats (LTR) and the first to demonstrate that a normal cellular protooncogene could be activated as an oncogene. These findings provided a foundation for the search for active oncogenes in tumors. In 1984, Dr. Vande Woude discovered human Met oncogene, a member of the tyrosine kinase growth factor receptor family that is altered in the majority of cancers. In addition to many basic scientific discoveries, his laboratory has also generated novel tools to help with drug development. Currently, his lab is developing novel preclinical models for evaluating the efficacy of tyrosine kinase inhibition in cancer patients.